Boehringer Ingelheim India Private Limited has entered into a strategic agreement with Alivira Animal Health Limited—a wholly owned subsidiary of Viyash Scientific Limited—for the distribution and promotion of its companion animal products portfolio in India. The collaboration is intended to strengthen Boehringer Ingelheim’s presence in the fast-expanding Indian pet healthcare segment, driven by rising pet ownership, increasing awareness of preventive care, and a stronger focus on animal well-being across the country. Under the agreement, Alivira Animal Health Limited will support broader market access for Boehringer Ingelheim’s companion animal range by expanding on-ground reach and sales execution across urban and rural markets.
Commenting on the partnership, Dr Vinod Gopal, Country Head, Animal Health, Boehringer Ingelheim India, said, “This agreement supports our long-term direction for animal health in India and helps us serve customers with greater consistency and focus. It enables scalable growth while keeping strategic leadership firmly in place. Through Alivira Animal Health Limited, we will strengthen our sales capability across both urban centres and rural regions, improving reach, access, and execution in the companion animal business.”
He added, “Our companion animal portfolio is built on high-quality products supported by a strong and progressing pipeline, ensuring sustainable growth and reliable delivery for customers. Working with Alivira Animal Health Limited will improve access and responsiveness while maintaining a clear strategy and consistent brand experience, supporting the future expansion of our companion animal business in India.”
Dr Haribabu Bodepudi, Managing Director & Group CEO, Viyash Scientific Limited, said the partnership marks an important step in the company’s growth in the pet care segment. “This collaboration represents a key milestone as we strengthen our role in the companion animal space. India presents significant opportunities for innovative medicines that address the medical needs of pets. Improving access to high-quality solutions for pet parents and veterinarians across both urban and rural India is central to this partnership. Alivira’s extensive distribution footprint and field capabilities, combined with Boehringer Ingelheim’s differentiated companion animal portfolio, will help serve the market more effectively,” he said.
Boehringer Ingelheim is a global biopharmaceutical company active in both human and animal health. It is among the leading industry investors in research and development, focused on delivering innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, the company operates with a long-term outlook and integrates sustainability across its value chain. Boehringer Ingelheim employs more than 53,500 people and serves over 130 markets worldwide.
Established in 2003, Boehringer Ingelheim India manages operations in India and neighbouring markets, offering products across Human Pharma and Animal Health. Its key therapy areas include diabetes, cardiovascular diseases, and respiratory conditions.
Alivira Animal Health Limited, as part of Viyash Scientific Limited (formerly Sequent Scientific Limited), operates within a global animal health platform. Headquartered in India, Viyash is among the top 25 animal health companies globally, with more than 3,000 employees and a portfolio covering formulations and APIs for both human and veterinary use. The group serves customers in over 100 countries and has manufacturing, R&D, and distribution operations across India, Spain, Brazil, Turkey, and the United States, with approvals from international regulatory bodies including USFDA, EU GMP, WHO, and TGA.